Recombinant Human Activated Protein C: Current Insights into Its Mechanism of Action

Overview

Journal Crit Care

Specialty Critical Care

Date 2008 Feb 27

PMID 18269690

Citations 16

Authors

Marcel Levi

Tom van der Poll

Affiliations

Soon will be listed here.

Abstract

Impairment of the protein C pathway plays a central role in the pathogenesis of sepsis. Administration of recombinant human activated protein C (rhAPC) may correct the dysregulated anticoagulant mechanism and prevent propagation of thrombin generation and formation of microvascular thrombosis. Furthermore, it may simultaneously modulate the inflammatory response. It is likely that the beneficial effect of rhAPC observed in experimental and clinical studies of severe sepsis results from a combination of mechanisms that modulate the entangled processes of coagulation and inflammation. This review presents an analysis of the various mechanisms of action of rhAPC in sepsis.

Citing Articles

UM171 induces a homeostatic inflammatory-detoxification response supporting human HSC self-renewal.

Chagraoui J, Lehnertz B, Girard S, Spinella J, Fares I, Tomellini E PLoS One. 2019; 14(11):e0224900.

PMID: 31703090 PMC: 6839847. DOI: 10.1371/journal.pone.0224900.

The contact pathway and sepsis.

Raghunathan V, Zilberman-Rudenko J, Olson S, Lupu F, McCarty O, Shatzel J Res Pract Thromb Haemost. 2019; 3(3):331-339.

PMID: 31294319 PMC: 6611366. DOI: 10.1002/rth2.12217.

Live liver donors: Are they at a higher risk for post-operative thrombotic complications?.

Hilmi I, Planinsic R World J Transplant. 2013; 2(1):1-4.

PMID: 24175189 PMC: 3812926. DOI: 10.5500/wjt.v2.i1.1.

Why activated protein C was not successful in severe sepsis and septic shock: are we still tilting at windmills?.

Lai P, Thompson B Curr Infect Dis Rep. 2013; 15(5):407-12.

PMID: 23925482 PMC: 3829688. DOI: 10.1007/s11908-013-0358-9.

Evaluation of recombinant activated protein C for severe sepsis at a tertiary academic medical center.

Anger K, DeGrado J, Greenwood B, Cohen S, Szumita P Ther Clin Risk Manag. 2013; 9:277-84.

PMID: 23766652 PMC: 3678900. DOI: 10.2147/TCRM.S45412.

References

Lay A, Donahue D, Tsai M, Castellino F . Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood. 2006; 109(5):1984-91. PMC: 1801051. DOI: 10.1182/blood-2006-07-037945. View

Laterre P . Clinical trials in severe sepsis with drotrecogin alfa (activated). Crit Care. 2008; 11 Suppl 5:S5. PMC: 2230609. DOI: 10.1186/cc6156. View

Levi M, Dorffler-Melly J, Reitsma P, Buller H, Florquin S, van der Poll T . Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood. 2003; 101(12):4823-7. DOI: 10.1182/blood-2002-10-3254. View

Riewald M, Petrovan R, Donner A, Mueller B, Ruf W . Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002; 296(5574):1880-2. DOI: 10.1126/science.1071699. View

Levi M, de Jonge E, van der Poll T . Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med. 2001; 29(7 Suppl):S90-4. DOI: 10.1097/00003246-200107001-00028. View

Levi M, ten Cate H . Disseminated intravascular coagulation. N Engl J Med. 1999; 341(8):586-92. DOI: 10.1056/NEJM199908193410807. View

Dhainaut J, Yan S, Joyce D, Pettila V, Basson B, Brandt J . Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004; 2(11):1924-33. DOI: 10.1111/j.1538-7836.2004.00955.x. View

Hancock W, Tsuchida A, Hau H, Thomson N, Salem H . The anticoagulants protein C and protein S display potent antiinflammatory and immunosuppressive effects relevant to transplant biology and therapy. Transplant Proc. 1992; 24(5):2302-3. View

Faust S, Levin M, Harrison O, Goldin R, Lockhart M, Kondaveeti S . Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med. 2001; 345(6):408-16. DOI: 10.1056/NEJM200108093450603. View

10.

Nick J, Coldren C, Geraci M, Poch K, Fouty B, OBrien J . Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood. 2004; 104(13):3878-85. DOI: 10.1182/blood-2004-06-2140. View

11.

Vary T, Kimball S . Regulation of hepatic protein synthesis in chronic inflammation and sepsis. Am J Physiol. 1992; 262(2 Pt 1):C445-52. DOI: 10.1152/ajpcell.1992.262.2.C445. View

12.

Oganesyan V, Oganesyan N, Terzyan S, Qu D, Dauter Z, Esmon N . The crystal structure of the endothelial protein C receptor and a bound phospholipid. J Biol Chem. 2002; 277(28):24851-4. DOI: 10.1074/jbc.C200163200. View

13.

Levi M, Levy M, Williams M, Douglas I, Artigas A, Antonelli M . Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am J Respir Crit Care Med. 2007; 176(5):483-90. DOI: 10.1164/rccm.200612-1803OC. View

14.

Kurosawa S, Esmon C, Stearns-Kurosawa D . The soluble endothelial protein C receptor binds to activated neutrophils: involvement of proteinase-3 and CD11b/CD18. J Immunol. 2000; 165(8):4697-703. DOI: 10.4049/jimmunol.165.8.4697. View

15.

Finigan J, Dudek S, Singleton P, Chiang E, Jacobson J, Camp S . Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem. 2005; 280(17):17286-93. DOI: 10.1074/jbc.M412427200. View

16.

Esmon C . The endothelial cell protein C receptor. Thromb Haemost. 2000; 83(5):639-43. View

17.

Fumagalli R, Mignini M . The safety profile of drotrecogin alfa (activated). Crit Care. 2008; 11 Suppl 5:S6. PMC: 2230610. DOI: 10.1186/cc6157. View

18.

De Backer D, Verdant C, Chierego M, Koch M, Gullo A, Vincent J . Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit Care Med. 2006; 34(7):1918-24. DOI: 10.1097/01.CCM.0000220498.48773.3C. View

19.

Feistritzer C, Riewald M . Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005; 105(8):3178-84. DOI: 10.1182/blood-2004-10-3985. View

20.

Vangerow B, Shorr A, Wyncoll D, Janes J, Nelson D, Reinhart K . The protein C pathway: implications for the design of the RESPOND study. Crit Care. 2008; 11 Suppl 5:S4. PMC: 2230608. DOI: 10.1186/cc6155. View